+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ophthalmic Drugs Market Size, Share & Trends Analysis Report by Drug Class, by Disease (Dry Eye, Glaucoma), by Dosage Form, by Route of Administration, by Product Type (Prescription, OTC), by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 150 Pages
  • October 2022
  • Region: Global
  • Grand View Research
  • ID: 4429696
Description Jump to:

Quick Summary:

In the fast-paced world of global health trends, the growing demand for advanced treatments and therapy in ophthalmology has led to an upswing in the ophthalmic drugs market. This escalating need is driven by an increase in global awareness and prevalence of various ocular disorders such as dry eye, diabetic retinopathy, and age-related macular degeneration, to name a few. The simultaneous rise in drugs tailored for these conditions is pushing the boundaries of this industry, reinforcing its progressive trajectory.

Anticipated growth in this market also stems from the mature and ever-expanding geriatric population, a demographic particularly prone to these conditions. Continuous strides made in medical R&D, propelled by ample funding, is catalyzing the development of innovative, effective drugs. Coupled with ongoing regulatory approvals for various ophthalmic products, this market is poised for continuous growth and offers lucrative opportunities for potential investors. Delve into the intricacies of this buoyant market with our comprehensive report, framing actionable insights and detailed analysis.

The global ophthalmic drugs market size is expected to reach USD 65.6 billion by 2030, garnering a CAGR of 7.7% from 2022 to 2030. The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth. Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs.

According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.

Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics’ EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.

Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA’s HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.

Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.

Ophthalmic Drugs Market Report Highlights

  • Anti-VEGF agents segment held the largest share in 2021 owing to their rising demand and lesser adverse effects
  • Retinal disorders held the largest market share in 2021 owing to the rising prevalence of age-related macular degeneration and diabetic retinopathy
  • The topical route of administration dominated the market in 2021 owing to factors such as the benefits of the topical route as it delivers the drug to the targeted site and ease of use
  • The eye drops segment is expected to hold the largest share in 2021 owing to rising demand for eye drops, high patient compliance, and availability of OTC products
  • Asia Pacific is expected to exhibit the fastest growth over the forecast period due to advancements in healthcare infrastructure, increasing demand for eye products, and a large patient pool


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Ophthalmic Drugs Market

What is the estimated value of the Global Ophthalmic Drugs Market?

The Global Ophthalmic Drugs Market was estimated to be valued at $35.8 Billion in 2022.

What is the growth rate of the Global Ophthalmic Drugs Market?

The growth rate of the Global Ophthalmic Drugs Market is 7.7%, with an estimated value of $65.6 Billion by 2030.

What is the forecasted size of the Global Ophthalmic Drugs Market?

The Global Ophthalmic Drugs Market is estimated to be worth $65.6 Billion by 2030.

Who are the key companies in the Global Ophthalmic Drugs Market?

Key companies in the Global Ophthalmic Drugs Market include Alcon, Novartis AG, Johnson & Johnson Services, Inc., Bausch Health, Merck & Co. Inc., Regeneron Pharmaceuticals, Inc., Coherus Biosciences, Inc., Allergan, Pfizer, Inc. and Bayer AG.
Report AttributeDetails
No. of Pages150
PublishedOctober 2022
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 35.8 Billion
Forecasted Market Value ( USD ) by 2030 $ 65.6 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned12

Table of Contents

Chapter 1 Ophthalmic Drugs Market: Methodology And Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 3: Country Wise Market Estimation Using Top Down Approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Ophthalmic Drugs Market: Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Ophthalmic Drugs Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market
3.2 Regulatory Framework
3.2.1 Regulatory Bodies, By Region
3.2.2 North America
3.2.3 Europe
3.2.4 Asia Pacific
3.2.5 Latin America
3.2.6 Middle East & Africa
3.3 Patent Expiry Analysis
3.4 Pipeline Analysis
3.4.1 Pipeline Analysis, By Phase (Funder Type- Industry)
3.4.2 Pipeline Analysis, By Phase (Funder Type- All Others)
3.5 Cost Structure Analysis
3.6 Market Dynamics
3.6.1 Market Drivers Analysis
3.6.1.1 Increasing Disease Prevalence
3.6.1.2 Strong Developmental Pipeline
3.6.1.3 Advancements In Drug Delivery
3.6.1.4 Promising Investment Scenario
3.6.2 Market Restraint Analysis
3.6.2.1 Patent Expiry Of Blockbuster Drugs
3.7 Penetration & Growth Prospect Mapping
3.8 Ophthalmic Drugs: Market Analysis Tools
3.8.1 Industry Analysis - Porter’s
3.8.2 Pestle Analysis
3.8.3 Major Deals And Strategic Alliances
3.8.3.1 New Product Launch
3.8.3.2 Acquisition
3.8.3.3 Expansion
3.8.3.4 Partnerships
3.8.3.5 Marketing & Promotions
3.9 Primary Research Analysis
3.9.1 Market Scenario
3.9.2 Key Kol Responses
Chapter 4 Ophthalmic Drugs Market: Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)
4.1 Definition and Scope
4.2 Drug Class Market Share Analysis, 2021 & 2030
4.3 Segment Dashboard
4.4 Global Ophthalmic Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
4.5 Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
4.5.1 Antiallergy
4.5.1.1 Antiallergy Market, 2018 - 2030 (USD Million)
4.5.2 Anti-Vegf Agents
4.5.2.1 Anti-Vegf Agents Market, 2018 - 2030 (USD Million)
4.5.3 Anti-Inflammatory
4.5.3.1 Anti-Inflammatory Market, 2018 - 2030 (USD Million)
4.5.3.2 Non-Steroidal Anti-Inflammatory Drugs
4.5.3.2.1 Non-Steroidal Anti-Inflammatory Market, 2018 - 2030 (USD Million)
4.5.3.3 Steroidal Anti-Inflammatory Drugs
4.5.3.3.1 Steroidal Anti-Inflammatory Market, 2018 - 2030 (USD Million)
4.5.4 Antiglaucoma
4.5.4.1 Antiglaucoma Market, 2018 - 2030 (USD Million)
4.5.5 Others
4.5.5.1 Others Market, 2018 - 2030 (USD Million)
Chapter 5 Ophthalmic Drugs Market: Segment Analysis, By Disease, 2018 - 2030 (USD Million)
5.1 Definition and Scope
5.2 Disease Market Share Analysis, 2021 & 2030
5.3 Segment Dashboard
5.4 Global Ophthalmic Drugs Market, by Disease, 2018 - 2030 (USD Million)
5.5 Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
5.5.1 Dry Eye
5.5.1.1 Dry Eye Market, 2018 - 2030 (USD Million)
5.5.2 Eye Allergies
5.5.2.1 Eye Allergies Market, 2018 - 2030 (USD Million)
5.5.3 Glaucoma
5.5.3.1 Glaucoma Market, 2018 - 2030 (USD Million)
5.5.4 Eye Infection
5.5.4.1 Eye Infection Market, 2018 - 2030 (USD Million)
5.5.5 Retinal Disorders
5.5.5.1 Retinal Disorders Market, 2018 - 2030 (USD Million)
5.5.5.2 Macular Degeneration
5.5.5.2.1 Macular Degeneration Market, 2018 - 2030 (USD Million)
5.5.5.3 Diabetic Retinopathy
5.5.5.3.1 Diabetic Retinopathy Market, 2018 - 2030 (USD Million)
5.5.5.4 Others
5.5.5.4.1 Others Market, 2018 - 2030 (USD Million)
5.5.6 Uveitis
5.5.6.1 Uveitis Market, 2018 - 2030 (USD Million)
5.5.7 Others
5.5.7.1 Others Market, 2018 - 2030 (USD Million)
Chapter 6 Ophthalmic Drugs Market: Segment Analysis, By Route of Administration, 2018 - 2030 (USD Million)
6.1 Definition and Scope
6.2 Route of Administration Market Share Analysis, 2021 & 2030
6.3 Segment Dashboard
6.4 Global Ophthalmic Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
6.5 Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
6.5.1 Topical
6.5.1.1 Topical Market, 2018 - 2030 (USD Million)
6.5.2 Local Ocular
6.5.2.1 Local Ocular Market, 2018 - 2030 (USD Million)
6.5.2.2 Subconjunctival
6.5.2.2.1 Subconjunctival Market, 2018 - 2030 (USD Million)
6.5.2.3 Intravitreal
6.5.2.3.1 Intravitreal Market, 2018 - 2030 (USD Million)
6.5.2.4 Retrobulbar
6.5.2.4.1 Retrobulbar Market, 2018 - 2030 (USD Million)
6.5.2.5 Intracameral
6.5.2.5.1 Intracameral Market, 2018 - 2030 (USD Million)
6.5.3 Systemic
6.5.3.1 Systemic Market, 2018 - 2030 (USD Million)
Chapter 7 Ophthalmic Drugs Market: Segment Analysis, By Dosage Form, 2018 - 2030 (USD Million)
7.1 Definition and Scope
7.2 Dosage Form Market Share Analysis, 2021 & 2030
7.3 Segment Dashboard
7.4 Global Ophthalmic Drugs Market, by Dosage Form, 2018 - 2030 (USD Million)
7.5 Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
7.5.1 Gels
7.5.1.1 Gels Market, 2018 - 2030 (USD Million)
7.5.2 Eye Solutions And Suspensions
7.5.2.1 Eye Solutions And Suspensions Market, 2018 - 2030 (USD Million)
7.5.3 Capsules & Tablets
7.5.3.1 Capsules & Tablets Market, 2018 - 2030 (USD Million)
7.5.4 Eye Drops
7.5.4.1 Eye Drops Market, 2018 - 2030 (USD Million)
7.5.5 Ointments
7.5.5.1 Ointments Market, 2018 - 2030 (USD Million)
Chapter 8 Ophthalmic Drugs Market: Segment Analysis, By Product Type, 2018 - 2030 (USD Million)
8.1 Definition and Scope
8.2 Product Type Market Share Analysis, 2021 & 2030
8.3 Segment Dashboard
8.4 Global Ophthalmic Drugs Market, by Product Type, 2018 - 2030 (USD Million)
8.5 Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
8.5.1 Otc Drugs
8.5.1.1 Otc Drugs Market, 2018 - 2030 (USD Million)
8.5.2 Prescription Drugs
8.5.2.1 Prescription Drugs Market, 2018 - 2030 (USD Million)
Chapter 9 Ophthalmic Drugs Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)
9.1 Definition & Scope
9.2 Regional Market Share Analysis, 2021 & 2030
9.3 Regional Market Dashboard
9.4 Regional Market Snapshot
9.5 Regional Market Share and Leading Players, 2021
9.5.1 North America
9.5.2 Europe
9.5.3 Asia Pacific
9.5.4 Latin America
9.5.5 Middle East & Africa
9.6 Swot Analysis
9.6.1 North America
9.6.2 Europe
9.6.3 Asia Pacific
9.6.4 Latin America
9.6.5 Middle East & Africa
9.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 - 2030 (USD Million)
9.7.1 North America
9.7.1.1 North America Ophthalmic Drugs Market, 2018-2030 (USD Million)
9.7.1.2 U.S.
9.7.1.2.1 U.S. Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.1.3 Canada
9.7.1.3.1 Canada Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.2 Europe
9.7.2.1 Europe Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.2.2 UK
9.7.2.2.1 UK Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.2.3 Germany
9.7.2.3.1 Germany Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.2.4 France
9.7.2.4.1 France Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.2.5 Italy
9.7.2.5.1 Italy Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.2.6 Spain
9.7.2.6.1 Spain Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.2.7 Russia
9.7.2.7.1 Russia Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.3 Asia PacificC
9.7.3.1 Asia Pacific Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.3.2 Japan
9.7.3.2.1 Japan Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.3.3 China
9.7.3.3.1 China Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.3.4 India
9.7.3.4.1 India Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.3.5 Australia
9.7.3.5.1 Australia Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.3.6 South Korea
9.7.3.6.1 South Korea Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.3.7 Singapore
9.7.3.7.1 Singapore Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.4 Latin America
9.7.4.1 Latin America Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.4.2 Mexico
9.7.4.2.1 Mexico Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.4.3 Brazil
9.7.4.3.1 Brazil Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.4.4 Argentina
9.7.4.4.1 Argentina Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.5 Middle East & Africa
9.7.5.1 Middle East & Africa Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.5.2 South Africa
9.7.5.2.1 South Africa Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.5.3 UAE
9.7.5.3.1 UAE Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
9.7.5.4 Saudi Arabia
9.7.5.4.1 Saudi Arabia Ophthalmic Drugs Market, 2018 - 2030 (USD Million)
Chapter 10 Ophthalmic Drugs Market: Competitive Analysis
10.1 Recent Developments & Impact Analysis, by Key Market Participants
10.1.1 Ansoff Matrix
10.1.2 Heat Map Analysis
10.2 Company Categorization
10.2.1 Innovators
10.2.2 Market Leaders
10.3 Vendor Landscape
10.3.1 List Of Key Distributors And Channel Partners
10.3.2 Key Customers
10.3.3 Key Company Market Share Analysis, 2021
10.4 Public Companies
10.4.1 Company Market Position Analysis
10.4.2 Company Market Share, By Region
10.4.3 Competitive Dashboard Analysis
10.4.3.1 Market Differentiators
10.5 Private Companies
10.5.1 List Of Key Emerging Companies
10.5.2 Regional Network Map
10.5.3 Company Market Position Analysis
10.6 Company Profiles
10.6.1 ALCON
10.6.1.1 Company Overview
10.6.1.2 Financial Performance
10.6.1.3 Product Benchmarking
10.6.1.4 Strategic Initiatives
10.6.2 NOVARTIS AG
10.6.2.1 Company Overview
10.6.2.2 Financial Performance
10.6.2.3 Product Benchmarking
10.6.2.4 Strategic Initiatives
10.6.3 JOHNSON & JOHNSON SERVICES, INC.
10.6.3.1 Company Overview
10.6.3.2 Financial Performance
10.6.3.3 Product Benchmarking
10.6.3.4 Strategic Initiatives
10.6.4 BAUSCH HEALTH
10.6.4.1 Company Overview
10.6.4.2 Financial Performance
10.6.4.3 Product Benchmarking
10.6.4.4 Strategic Initiatives
10.6.5 MERCK & CO. INC.
10.6.5.1 Company Overview
10.6.5.2 Financial Performance
10.6.5.3 Product Benchmarking
10.6.5.4 Strategic Initiatives
10.6.6 REGENERON PHARMACEUTICALS, INC.
10.6.6.1 Company Overview
10.6.6.2 Financial Performance
10.6.6.3 Product Benchmarking
10.6.6.4 Strategic Initiatives
10.6.7 COHERUS BIOSCIENCES, INC.
10.6.7.1 Company Overview
10.6.7.2 Financial Performance
10.6.7.3 Product Benchmarking
10.6.7.4 Strategic Initiatives
10.6.8 ALLERGAN
10.6.8.1 Company Overview
10.6.8.2 Financial Performance
10.6.8.3 Product Benchmarking
10.6.8.4 Strategic Initiatives
10.6.9 PFIZER, INC.
10.6.9.1 Company Overview
10.6.9.2 Financial Performance
10.6.9.3 Product Benchmarking
10.6.9.4 Strategic Initiatives
10.6.10 BAYER AG
10.6.10.1 Company Overview
10.6.10.2 Financial Performance
10.6.10.3 Product Benchmarking
10.6.10.4 Strategic Initiatives
10.6.11 SANTEN PHARMACEUTICALS CO. LTD.
10.6.11.1 Company Overview
10.6.11.2 Financial Performance
10.6.11.3 Product Benchmarking
10.6.11.4 Strategic Initiatives
10.6.12 GENETECH, INC.
10.6.12.1 Company Overview
10.6.12.2 Financial Performance
10.6.12.3 Product Benchmarking
10.6.12.4 Strategic Initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 Global Ophthalmic Drugs Market, by Region, 2018-2030 (USD Million)
Table 3 Global Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 4 Global Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 5 Global Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 6 Global Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 7 North America Ophthalmic Drugs Market, by Country, 2018-2030 (USD Million)
Table 8 North America Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 9 North America Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 10 North America Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 11 North America Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 12 North America Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 13 U.S. Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 14 U.S. Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 15 U.S. Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 16 U.S. Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 17 U.S. Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 18 Canada Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 19 Canada Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 20 Canada Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 21 Canada Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 22 Canada Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 23 Europe Ophthalmic Drugs Market, by Country, 2018-2030 (USD Million)
Table 24 Europe Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 25 Europe Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 26 Europe Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 27 Europe Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 28 Europe Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 29 U.K. Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 30 U.K. Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 31 U.K. Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 32 U.K. Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 33 U.K. Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 34 Germany Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 35 Germany Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 36 Germany Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 37 Germany Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 38 Germany Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 39 France Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 40 France Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 41 France Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 42 France Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 43 France Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 44 Spain Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 45 Spain Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 46 Spain Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 47 Spain Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 48 Spain Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 49 Italy Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 50 Italy Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 51 Italy Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 52 Italy Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 53 Italy Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 54 Russia Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 55 Russia Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 56 Russia Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 57 Russia Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 58 Russia Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 59 Asia Pacific Ophthalmic Drugs Market, by Country, 2018-2030 (USD Million)
Table 60 Asia Pacific Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 61 Asia Pacific Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 62 Asia Pacific Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 63 Asia Pacific Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 64 Asia Pacific Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 65 Japan Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 66 Japan Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 67 Japan Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 68 Japan Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 69 Japan Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 70 China Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 71 China Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 72 China Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 73 China Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 74 China Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 75 India Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 76 India Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 77 India Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 78 India Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 79 India Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 80 South Korea Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 81 South Korea Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 82 South Korea Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 83 South Korea Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 84 South Korea Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 85 Australia Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 86 Australia Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 87 Australia Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 88 Australia Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 89 Australia Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 90 Singapore Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 91 Singapore Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 92 Singapore Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 93 Singapore Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 94 Singapore Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 95 Latin America Ophthalmic Drugs Market, by Country, 2018-2030 (USD Million)
Table 96 Latin America Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 97 Latin America Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 98 Latin America Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 99 Latin America Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 100 Latin America Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 101 Brazil Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 102 Brazil Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 103 Brazil Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 104 Brazil Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 105 Brazil Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 106 Argentina Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 107 Argentina Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 108 Argentina Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 109 Argentina Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 110 Argentina Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 111 Mexico Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 112 Mexico Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 113 Mexico Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 114 Mexico Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 115 Mexico Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 116 Middle East and Africa Ophthalmic Drugs Market, by Country, 2018-2030 (USD Million)
Table 117 Middle East and Africa Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 118 Middle East and Africa Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 119 Middle East and Africa Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 120 Middle East and Africa Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 121 Middle East and Africa Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 122 South Africa Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 123 South Africa Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 124 South Africa Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 125 South Africa Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 126 South Africa Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 127 UAE Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 128 UAE Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 129 UAE Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 130 UAE Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 131 UAE Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
Table 132 Saudi Arabia Ophthalmic Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 133 Saudi Arabia Ophthalmic Drugs Market, by Disease, 2018-2030 (USD Million)
Table 134 Saudi Arabia Ophthalmic Drugs Market, by Dosage Form, 2018-2030 (USD Million)
Table 135 Saudi Arabia Ophthalmic Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 136 Saudi Arabia Ophthalmic Drugs Market, by Product Type, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market summary
Fig. 4 Market segmentation & scope
Fig. 5 Market size and growth prospects
Fig. 6 Global ophthalmic drugs- Key market driver analysis
Fig. 7 Global ophthalmic drugs market-Key market restraint analysis
Fig. 8 Penetration & growth prospect mapping
Fig. 9 Factors estimated to impact on market growth
Fig. 10 Global ophthalmic drugs market-Porter’s analysis
Fig. 11 Global ophthalmic drugs market-PESTEL analysis
Fig. 12 Global ophthalmic drugs market drug class outlook key takeaways
Fig. 13 Global ophthalmic drugs market: Drug class movement analysis
Fig. 14 Antiallergy market estimates, 2018-2030 (USD Million)
Fig. 15 Anti-VEGF agents market estimates, 2018-2030 (USD Million)
Fig. 16 Anti-inflammatory market estimates, 2018-2030 (USD Million)
Fig. 17 Non-steroidal drugs market estimates, 2018-2030 (USD Million)
Fig. 18 Steroidal market estimates, 2018-2030 (USD Million)
Fig. 19 Antiglaucoma market estimates, 2018-2030 (USD Million)
Fig. 20 Others market estimates, 2018-2030 (USD Million)
Fig. 21 Global ophthalmic drugs market disease outlook key takeaways
Fig. 22 Global ophthalmic drugs market: Disease movement analysis
Fig. 23 Dry eye market estimates, 2018-2030 (USD Million)
Fig. 24 Eye allergy market estimates, 2018-2030 (USD Million)
Fig. 25 Glaucoma market estimates, 2018-2030 (USD Million)
Fig. 26 Eye infection market estimates, 2018-2030 (USD Million)
Fig. 27 Retinal disorders market estimates, 2018-2030 (USD Million)
Fig. 28 Macular degeneration market estimates, 2018-2030 (USD Million)
Fig. 29 Diabetic retinopathy market estimates, 2018-2030 (USD Million)
Fig. 30 Others market estimates, 2018-2030 (USD Million)
Fig. 31 Uveitis market estimates, 2018-2030 (USD Million)
Fig. 32 Others market estimates, 2018-2030 (USD Million)
Fig. 33 Global ophthalmic drugs market dosage form outlook key takeaways
Fig. 34 Global ophthalmic drugs market: Dosage type movement analysis
Fig. 35 Gels market estimates, 2018-2030 (USD Million)
Fig. 36 Eye solutions and suspension market estimates, 2018-2030 (USD Million)
Fig. 37 Capsules & tablets market estimates, 2018-2030 (USD Million)
Fig. 38 Eye drops market estimates, 2018-2030 (USD Million)
Fig. 39 Ointments market estimates, 2018-2030 (USD Million)
Fig. 40 Global ophthalmic drugs market route of administration outlook key takeaways
Fig. 41 Global ophthalmic drugs market: Route of administration movement analysis
Fig. 42 Topical market estimates, 2018-2030 (USD Million)
Fig. 43 Local ocular market estimates, 2018-2030 (USD Million)
Fig. 44 Subconjunctival market estimates, 2018-2030 (USD Million)
Fig. 45 Intravitreal market estimates, 2018-2030 (USD Million)
Fig. 46 Retrobulbar market estimates, 2018-2030 (USD Million)
Fig. 47 Intracameral market estimates, 2018-2030 (USD Million)
Fig. 48 Systemic market estimates, 2018-2030 (USD Million)
Fig. 49 Global ophthalmic drugs market product type outlook key takeaways
Fig. 50 Global ophthalmic drugs market: Product type movement analysis
Fig. 51 Prescription drugs market estimates, 2018-2030 (USD Million)
Fig. 52 OTC drugs market estimates, 2018-2030 (USD Million)
Fig. 53 Regional market place: Key takeaways
Fig. 54 Global ophthalmic drugs market: Regional movement analysis
Fig. 55 North America ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 56 U.S. ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 57 Canada ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 58 Europe ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 59 U.K. ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 60 Germany ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 61 France ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 62 Spain ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 63 Italy ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 64 Russia ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 65 Asia Pacific ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 66 Japan ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 67 China ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 68 India ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 69 South Korea ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 70 Singapore ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 71 Australia ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 72 Latin America ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 73 Brazil ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 74 Mexico ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 75 Argentina ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 76 Middle East & Africa ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 77 South Africa ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 78 UAE ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 79 Saudi Arabia ophthalmic drugs market, 2018-2030 (USD Million)
Fig. 80 Strategy framework

Companies Mentioned

  • Alcon
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Bausch Health
  • Merck & Co. Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Coherus Biosciences, Inc.
  • Allergan
  • Pfizer, Inc.
  • Bayer AG
  • Santen Pharmaceuticals Co. Ltd.
  • Genetech, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Optical Disorders Drugs Market - Global Industry Size, Share, Trends Opportunity, and Forecast 2018-2028 - Product Image

Optical Disorders Drugs Market - Global Industry Size, Share, Trends Opportunity, and Forecast 2018-2028

  • Report
  • 171 Pages
  • Global
From
Global Ophthalmic Drugs Market by Dispense Type (Over the Counter, Prescription), Disease Condition (Allergy, Dry Eye Disorder, Glaucoma), Products, Dosage Form, Distribution - Forecast 2023-2030 - Product Image

Global Ophthalmic Drugs Market by Dispense Type (Over the Counter, Prescription), Disease Condition (Allergy, Dry Eye Disorder, Glaucoma), Products, Dosage Form, Distribution - Forecast 2023-2030

  • Report
  • 199 Pages
  • Global
From
Global Ophthalmic Drug Delivery System Market by Technology (Contact Lenses, Episcleral Implants, Eye Drops), Production Technology (3D Printing, Compression Molding, Electrospinning), Material, Delivery Route - Forecast 2023-2030 - Product Image

Global Ophthalmic Drug Delivery System Market by Technology (Contact Lenses, Episcleral Implants, Eye Drops), Production Technology (3D Printing, Compression Molding, Electrospinning), Material, Delivery Route - Forecast 2023-2030

  • Report
  • 184 Pages
  • Global
From
Global Ophthalmic Disease Therapeutics Market Analysis & Forecast to 2023-2033: Market By Drug Class; By Disease; By Dosage Form; By Product; By Route of Administration; and By Region - Product Image

Global Ophthalmic Disease Therapeutics Market Analysis & Forecast to 2023-2033: Market By Drug Class; By Disease; By Dosage Form; By Product; By Route of Administration; and By Region

  • Report
  • 145 Pages
  • Global
From
Copyright © 2002-2023 Research and Markets. All Rights Reserved.